KROS Keros Therapeutics, Inc.

NASDAQ
$11.08

Keros Therapeutics, Inc. (KROS) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with KROS's own trailing one-year pace, with 0% of sale value under a prearranged plan.
Cluster activity 1 buyer in the last 30 days 1 buyer in the last 90 days 4 sellers in the last 90 days
Insiders buying
1
6 transactions
Insiders selling
10
19 transactions
Purchases
$75.8K
7,000 shares
Sales
$181.2M
10,215,220 shares
Net activity
-$181.1M
purchases less sales

How much of that selling was preplanned? 0% planned / 100% discretionary

10b5-1 plan sales $95.7K 5 transactions · 8,976 shares
Discretionary sales $181.1M 14 transactions · 10,206,244 shares

Largest single sale: $77.9M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

Last open-market purchase: August 17, 2026 , by BIENAIME JEAN JACQUES .

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Cho Esther Chief Legal Officer Sell 4,485 $10.29 $46.2K 35,770 −11.1% of holding
Lerner Lorena Raquel Chief Scientific Officer Sell 3,568 $10.29 $36.7K 27,559 −11.5% of holding
Tanini Annita Corp. Controller & VP, Finance Sell 1,224 $10.29 $12.6K 45,144 −2.6% of holding
Newton Charles W. Director Sell 10b5-1 551 $10.30 $5.7K 12,114 −4.4% of holding
BIENAIME JEAN JACQUES Director Buy 10b5-1 1,000 $10.27 $10.3K 19,592
BIENAIME JEAN JACQUES Director Buy 10b5-1 1,000 $10.61 $10.6K 18,592
BIENAIME JEAN JACQUES Director Buy 10b5-1 1,000 $10.19 $10.2K 17,592
Newton Charles W. Director Sell 10b5-1 550 $10.04 $5.5K 12,665 −4.2% of holding
Farzan Nima Director Sell 10b5-1 2,625 $10.73 $28.2K 9,767 −21.2% of holding
Knowles Julius Director Sell 10b5-1 2,625 $10.73 $28.2K 10,958 −19.3% of holding
Seth Alpna Director Sell 10b5-1 2,625 $10.72 $28.1K 9,767 −21.2% of holding
BIENAIME JEAN JACQUES Director Buy 10b5-1 1,000 $10.58 $10.6K 9,450
BIENAIME JEAN JACQUES Director Buy 10b5-1 1,000 $11.70 $11.7K 8,450
BIENAIME JEAN JACQUES Director Buy 10b5-1 2,000 $11.21 $22.4K 7,450
Seehra Jasbir CHIEF EXECUTIVE OFFICER Sell 7,015 $16.17 $113.4K 385,708 −1.8% of holding
Cho Esther SVP, General Counsel Sell 4,745 $16.35 $77.6K 39,755 −10.7% of holding
Regnante Keith CHIEF FINANCIAL OFFICER Sell 4,739 $16.35 $77.5K 39,261 −10.8% of holding
Lerner Lorena Raquel Chief Science Officer Sell 3,873 $16.35 $63.3K 31,127 −11.1% of holding
7 fills Sell 10,176,595 $17.75 $180.6M None left

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.